Imaging agent scans in advanced bladder, breast and lung cancers
Tests an imaging agent in adults with advanced urothelial, breast or lung cancer.
Key facts
- Who runs it
- RayzeBio, Inc.
- Where
- Christchurch, New ZealandSee the siteAlso in 2 other countries, 5 sites
- Trial code
- Registry title
- Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 40 people, planned
- Started
- 15 Jun 2026
- Expected to end
- Nov 2027
- Type of study
- Interventional
- Treatments tested
- RYZ211/212
- Record updated
- 13 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with metastatic urothelial cancer, hormone receptor-positive HER2-negative breast cancer, triple-negative breast cancer, or non-small-cell lung cancer. It tests an imaging agent.
- Age
- 18 years or older
- Sex
- Women and men can join.
- Disease stage
- Metastatic urothelial cancer, HR+ and HER2- breast cancer, triple-negative breast cancer, or non-small-cell lung cancer, proven by biopsy.
Main reasons for not taking part
- Women who can have children and are pregnant or breastfeeding
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Are at least 18 years old at the time of signing the informed consent form (ICF)
- Have biopsy proven metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC
Who cannot take part
- For Women of Childbearing Potential: Are pregnant or breastfeeding; Note: Additional criteria may apply and will be assessed by the study site
This trial is currently available in New Zealand.
Also in 2 other countries, 5 sites
- ChristchurchHospital not named in the registryContact: RayzeBio Clinical TrialsTaking people
About the trial
What the trial wants to find out
This imaging study aims to assess the feasibility, biodistribution, and dosimetry of the imaging agent in subjects with metastatic UC, HR+ and HER2- breast cancer, TNBC, or NSCLC.
The group in the trial
- RYZ211/212Treatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 0 Imaging Study to Assess the Feasibility, Biodistribution, and Dosimetry of the Imaging Agent in Metastatic Urothelial Cancer (UC), Hormone Receptor-Positive (HR+) and Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Breast Cancer, Triple-Negative Breast Cancer (TNBC), and Non-Small-Cell Lung Cancer (NSCLC)
- Plain-language title
- Imaging agent scans in advanced bladder, breast and lung cancersGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 13 October 2026